Sutro Biopharma Stock Forecast - Triple Exponential Smoothing
| STRO Stock | USD 15.50 1.12 6.74% |
Sutro Stock outlook is based on your current time horizon. Although Sutro Biopharma's naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Sutro Biopharma's systematic risk associated with finding meaningful patterns of Sutro Biopharma fundamentals over time.
The RSI of Sutro Biopharma's stock price is about 60. This usually implies that the stock is rather overbought by investors as of today. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Sutro, making its price go up or down. Momentum 60
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.28) | EPS Estimate Current Year (1.94) | EPS Estimate Next Year (1.17) | Wall Street Target Price 2.6857 | EPS Estimate Current Quarter (0.33) |
Using Sutro Biopharma hype-based prediction, you can estimate the value of Sutro Biopharma from the perspective of Sutro Biopharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Sutro Biopharma using Sutro Biopharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Sutro using crowd psychology based on the activity and movement of Sutro Biopharma's stock price.
Sutro Biopharma Short Interest
An investor who is long Sutro Biopharma may also wish to track short interest. As short interest increases, investors should be becoming more worried about Sutro Biopharma and may potentially protect profits, hedge Sutro Biopharma with its derivative instruments, or be ready for some potential downside.
200 Day MA 0.9827 | Short Percent 0.0401 | Short Ratio 2.37 | Shares Short Prior Month 560.3 K | 50 Day MA 0.941 |
Sutro Relative Strength Index
The Triple Exponential Smoothing forecasted value of Sutro Biopharma on the next trading day is expected to be 15.81 with a mean absolute deviation of 0.53 and the sum of the absolute errors of 31.55.Sutro Biopharma Hype to Price Pattern
Investor biases related to Sutro Biopharma's public news can be used to forecast risks associated with an investment in Sutro. The trend in average sentiment can be used to explain how an investor holding Sutro can time the market purely based on public headlines and social activities around Sutro Biopharma. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Sutro Biopharma's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Sutro Biopharma.
Sutro Biopharma Implied Volatility | 2.59 |
Sutro Biopharma's implied volatility exposes the market's sentiment of Sutro Biopharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Sutro Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Sutro Biopharma stock will not fluctuate a lot when Sutro Biopharma's options are near their expiration.
The Triple Exponential Smoothing forecasted value of Sutro Biopharma on the next trading day is expected to be 15.81 with a mean absolute deviation of 0.53 and the sum of the absolute errors of 31.55. Sutro Biopharma after-hype prediction price | USD 17.06 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Sutro Biopharma to cross-verify your projections. Prediction based on Rule 16 of the current Sutro contract
Based on the Rule 16, the options market is currently suggesting that Sutro Biopharma will have an average daily up or down price movement of about 0.16% per day over the life of the 2026-03-20 option contract. With Sutro Biopharma trading at USD 15.5, that is roughly USD 0.0251 . If you think that the market is fully incorporating Sutro Biopharma's daily price movement you should consider acquiring Sutro Biopharma options at the current volatility level of 2.59%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-03-20 Sutro Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Sutro Biopharma's spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Sutro Biopharma's options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Sutro Biopharma stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Sutro Biopharma's open interest, investors have to compare it to Sutro Biopharma's spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Sutro Biopharma is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Sutro. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Sutro Biopharma Additional Predictive Modules
Most predictive techniques to examine Sutro price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Sutro using various technical indicators. When you analyze Sutro charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Sutro Biopharma Triple Exponential Smoothing Price Forecast For the 29th of January
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Sutro Biopharma on the next trading day is expected to be 15.81 with a mean absolute deviation of 0.53, mean absolute percentage error of 0.48, and the sum of the absolute errors of 31.55.Please note that although there have been many attempts to predict Sutro Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Sutro Biopharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Sutro Biopharma Stock Forecast Pattern
| Backtest Sutro Biopharma | Sutro Biopharma Price Prediction | Buy or Sell Advice |
Sutro Biopharma Forecasted Value
In the context of forecasting Sutro Biopharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Sutro Biopharma's downside and upside margins for the forecasting period are 9.19 and 22.42, respectively. We have considered Sutro Biopharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Sutro Biopharma stock data series using in forecasting. Note that when a statistical model is used to represent Sutro Biopharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.127 |
| MAD | Mean absolute deviation | 0.5347 |
| MAPE | Mean absolute percentage error | 0.0513 |
| SAE | Sum of the absolute errors | 31.5452 |
Predictive Modules for Sutro Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sutro Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sutro Biopharma After-Hype Price Density Analysis
As far as predicting the price of Sutro Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Sutro Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Sutro Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Sutro Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Sutro Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Sutro Biopharma's historical news coverage. Sutro Biopharma's after-hype downside and upside margins for the prediction period are 10.45 and 23.67, respectively. We have considered Sutro Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Sutro Biopharma is unstable at this time. Analysis and calculation of next after-hype price of Sutro Biopharma is based on 3 months time horizon.
Sutro Biopharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Sutro Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sutro Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Sutro Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.81 | 6.61 | 0.44 | 0.37 | 11 Events / Month | 6 Events / Month | In about 11 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
15.50 | 17.06 | 2.65 |
|
Sutro Biopharma Hype Timeline
Sutro Biopharma is at this time traded for 15.50. The entity has historical hype elasticity of 0.44, and average elasticity to hype of competition of 0.37. Sutro is projected to increase in value after the next headline, with the price projected to jump to 17.06 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 2.65%, whereas the daily expected return is at this time at 0.81%. The volatility of related hype on Sutro Biopharma is about 1465.63%, with the expected price after the next announcement by competition of 15.87. Sutro Biopharma currently holds 23.15 M in liabilities with Debt to Equity (D/E) ratio of 0.27, which may suggest the company is not taking enough advantage from borrowing. Given the investment horizon of 90 days the next projected press release will be in about 11 days. Check out Historical Fundamental Analysis of Sutro Biopharma to cross-verify your projections.Sutro Biopharma Related Hype Analysis
Having access to credible news sources related to Sutro Biopharma's direct competition is more important than ever and may enhance your ability to predict Sutro Biopharma's future price movements. Getting to know how Sutro Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Sutro Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ARTV | Artiva Biotherapeutics Common | 2.21 | 6 per month | 7.55 | 0.05 | 10.83 | (11.11) | 118.69 | |
| ADVM | Adverum Biotechnologies | 0.02 | 12 per month | 3.70 | 0.07 | 10.34 | (6.79) | 40.97 | |
| DTIL | Precision BioSciences | 0.16 | 17 per month | 0.00 | (0.18) | 5.99 | (8.82) | 28.04 | |
| PLRX | Pliant Therapeutics | 0.02 | 3 per month | 0.00 | (0.15) | 4.58 | (6.71) | 22.72 | |
| GUTS | Fractyl Health Common | 0.29 | 8 per month | 2.84 | 0.16 | 11.89 | (5.49) | 26.39 | |
| IFRX | InflaRx NV | 0.02 | 9 per month | 0.00 | (0.03) | 10.61 | (9.17) | 43.11 | |
| MGX | Metagenomi Common Stock | 0.02 | 10 per month | 0.00 | (0.18) | 6.02 | (8.57) | 19.55 | |
| CNTB | Connect Biopharma Holdings | (0.02) | 8 per month | 3.77 | 0.14 | 11.89 | (5.88) | 36.83 | |
| STTK | Shattuck Labs | 0.02 | 12 per month | 2.78 | 0.26 | 7.29 | (4.55) | 27.07 | |
| KLRS | Kalaris Therapeutics | 1.77 | 8 per month | 4.39 | 0.19 | 15.58 | (8.21) | 32.70 |
Other Forecasting Options for Sutro Biopharma
For every potential investor in Sutro, whether a beginner or expert, Sutro Biopharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Sutro Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Sutro. Basic forecasting techniques help filter out the noise by identifying Sutro Biopharma's price trends.Sutro Biopharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sutro Biopharma stock to make a market-neutral strategy. Peer analysis of Sutro Biopharma could also be used in its relative valuation, which is a method of valuing Sutro Biopharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Sutro Biopharma Market Strength Events
Market strength indicators help investors to evaluate how Sutro Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Sutro Biopharma shares will generate the highest return on investment. By undertsting and applying Sutro Biopharma stock market strength indicators, traders can identify Sutro Biopharma entry and exit signals to maximize returns.
| Rate Of Daily Change | 0.93 | |||
| Day Median Price | 15.5 | |||
| Day Typical Price | 15.5 | |||
| Price Action Indicator | (0.56) | |||
| Period Momentum Indicator | (1.12) | |||
| Relative Strength Index | 60.86 |
Sutro Biopharma Risk Indicators
The analysis of Sutro Biopharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Sutro Biopharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting sutro stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 5.23 | |||
| Semi Deviation | 5.4 | |||
| Standard Deviation | 6.71 | |||
| Variance | 44.97 | |||
| Downside Variance | 34.99 | |||
| Semi Variance | 29.21 | |||
| Expected Short fall | (6.12) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Sutro Biopharma
The number of cover stories for Sutro Biopharma depends on current market conditions and Sutro Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Sutro Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Sutro Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Sutro Biopharma Short Properties
Sutro Biopharma's future price predictability will typically decrease when Sutro Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Sutro Biopharma often depends not only on the future outlook of the potential Sutro Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sutro Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7.7 M | |
| Cash And Short Term Investments | 316.9 M |
Check out Historical Fundamental Analysis of Sutro Biopharma to cross-verify your projections. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.